Stifel analyst Jonathan Block lowered his price target lowered to $16 from $19 saying that while Q4 results were largely known, the company provided a tempered first half of 2019 outlook. The analyst notes that Sientra had already preannounced Q4 results in January, but points out that there were a couple of incremental data points on the conference call that may exert some near-term pressure on the stock, including recent headlines surrounding ALCL and textured implants that have pressured the number of Plastic Surgeon breast augmentation consultations in Q1, which may continue into Q2. Nonetheless, Block reiterates a Buy rating on the shares.